1224724-39-3

Basic information

• Product Name: 1H-Indole-7-carboxylic acid, 4-broMo-, Methyl ester
• Synonyms: 1H-Indole-7-carboxylic acid, 4-broMo-, Methyl ester;Methyl 4-broMo-1H-indole-7-carboxylate
• CAS NO: 1224724-39-3
• Molecular Formula: C₁₀H₈BrNO₂
• Molecular Weight: 254.08002
• Mol File: 1224724-39-3.mol

Chemical Properties

• Boiling Point: 402.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.629±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.49±0.30(Predicted)
• CAS DataBase Reference: 1H-Indole-7-carboxylic acid, 4-broMo-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-7-carboxylic acid, 4-broMo-, Methyl ester(1224724-39-3)
• EPA Substance Registry System: 1H-Indole-7-carboxylic acid, 4-broMo-, Methyl ester(1224724-39-3)

Safety Data

• Hazardous Substances Data: 1224724-39-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1H-Indole-7-carboxylic acid, 4-bromo-, methyl ester is used as a reagent in organic synthesis and pharmaceutical research for its potential role in the development of new drugs. The 4-bromo substitution on the indole ring may contribute to its biological activities and therapeutic properties, making it a valuable compound for exploring potential pharmaceutical applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Indole-7-carboxylic acid, 4-bromo-, methyl ester is utilized as a building block for the synthesis of novel compounds with potential therapeutic effects. Its unique structure allows for further chemical modifications, enabling the design of new molecules with improved pharmacological properties.
Used in Drug Development:
1H-Indole-7-carboxylic acid, 4-bromo-, methyl ester is employed in drug development as a starting material for the synthesis of potential drug candidates. Its presence in various plants and animals suggests that it may possess bioactive properties that can be harnessed for therapeutic purposes. The 4-bromo substitution on the indole ring may enhance its pharmacological activity, making it a promising candidate for the development of new drugs.

Upstream product

• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 1826-67-1 vinyl magnesium bromide 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 
• 1211594-25-0 4-bromo-1H-indole-7-carboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1211596-82-5 4-bromo-1H-indole-7-carboxamide 
• 1309980-17-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide 

Relevant articles and documents

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

Indolo-quinoline boron difluoride dyes: Synthesis and spectroscopic properties

Novel indolo-quinoline compounds were efficiently prepared via a Povarov-type reaction, and the structures were further modified by a Suzuki coupling reaction. The corresponding BF2-rigidified complexes were prepared and their spectroscopic properties were characterized with large Stokes shifts (up to 211 nm) and up to near-infrared (NIR) wavelength (667 nm). The synthetic complexes could be used as new fluorescent dyes.

PRIMARY CARBOXAMIDES AS BTK INHIBITORS

The invention provides carboxamide compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions, including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing spondylitis, interstitial cystitis, asthma, systemic lupus erythematosus, lupus nephritis, B cell chronic lymphocytic lymphoma, multiple sclerosis, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's lymphoma, activated B-celllike diffuse large B-cell, lymphoma, multiple myeloma, diffuse large B-celllymphoma, follicular lymphoma, hairy cell leukemia or Lymphoblastic lymphoma.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.